Literature DB >> 17192854

Risk factors for new-onset diabetes mellitus following liver transplantation and impact of hepatitis C infection : an observational multicenter study.

Faouzi Saliba1, Mohamed Lakehal, Georges-Philippe Pageaux, Bruno Roche, Claire Vanlemmens, Christophe Duvoux, Jérôme Dumortier, Ephrem Salamé, Yvon Calmus, Didier Maugendre.   

Abstract

New-onset diabetes mellitus (NODM) remains a common complication of liver transplantation (LT). We studied incidence and risk factors in 211 French patients who had undergone a primary LT between 6 and 24 months previously. This is a cross-sectional and retrospective multicenter study. Data were collected on consecutive patients at a single routine post-LT consultation. Demographic details, immunosuppressive regimens, familial and personal histories, hepatitis status, and cardiovascular risk were analyzed to compare those who developed NODM (American Diabetes Association/World Health Organization criteria) with the others. The overall incidence of NODM was 22.7%: 24% in tacrolimus (Tac)-treated patients (n = 175; 82.9%) and 16.7% in cyclosporine-treated patients (n = 36; 17.1%). A total of 81% of the cases were diagnosed within 3 months of LT (M3). Among hepatitis C virus (HCV)-infected (HCV(+)) patients, NODM incidence was 41.7% whereas among those patients negative for this virus (HCV(-)), the incidence was only 18.9% (P = 0.008). In Tac-treated patients, the incidence of NODM in the HCV(+) patients was significantly higher than in the HCV(-) patients (46.7% and 19.3%, respectively, P = 0.0014). Only 1 of 6 (16.7%) of the HCV(+) patients developed NODM on cyclosporine. Other independent pretransplantation risk factors for NODM included impaired fasting glucose (IFG) and a maximum lifetime body-mass index (BMI) over 25 kg/m2. In conclusion, emergence of NODM after LT is related to risk factors that can be detected prior to the graft, like maximum lifetime BMI, IFG, and HCV status. Tac induced a significantly higher incidence of NODM in the HCV(+) compared to the HCV(-) patients. The treatment should therefore be tailored to the patient's risk especially in case of HCV infection. (c) 2006 AASLD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17192854     DOI: 10.1002/lt.21010

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  29 in total

Review 1.  Risk factors for new onset diabetes mellitus after liver transplantation: A meta-analysis.

Authors:  Da-Wei Li; Tian-Fei Lu; Xiang-Wei Hua; Hui-Juan Dai; Xiao-Lan Cui; Jian-Jian Zhang; Qiang Xia
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

2.  Association between E23K variant in KCNJ11 gene and new-onset diabetes after liver transplantation.

Authors:  Zahra Parvizi; Negar Azarpira; Leila Kohan; Masumeh Darai; Kourosh Kazemi; Mohamad Mehdi Parvizi
Journal:  Mol Biol Rep       Date:  2014-07-05       Impact factor: 2.316

3.  Impact of preexisting diabetes mellitus on outcome after liver transplantation in patients with hepatitis B virus-related liver disease.

Authors:  Qi Ling; Xiao Xu; Qiang Wei; Xuyong Wei; Zhuoyi Wang; Lin Zhou; Shusen Zheng
Journal:  Dig Dis Sci       Date:  2010-08-12       Impact factor: 3.199

4.  New-onset diabetes mellitus after living-donor liver transplantation: association with graft synthetic function.

Authors:  Shintaro Yagi; Toshimi Kaido; Taku Iida; Atsushi Yoshizawa; Hideaki Okajima; Shinji Uemoto
Journal:  Surg Today       Date:  2016-11-11       Impact factor: 2.549

Review 5.  Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.

Authors:  Vijay Shivaswamy; Brian Boerner; Jennifer Larsen
Journal:  Endocr Rev       Date:  2015-12-09       Impact factor: 19.871

Review 6.  Natural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.

Authors:  Jérôme Dumortier; Olivier Boillot; Jean-Yves Scoazec
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

7.  Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance.

Authors:  Aymin Delgado-Borrego; Yun-Sheen Liu; Sergio H Jordan; Saurabh Agrawal; Hui Zhang; Marielle Christofi; Deborah Casson; A Benedict Cosimi; Raymond T Chung
Journal:  Liver Transpl       Date:  2008-02       Impact factor: 5.799

Review 8.  Hepatitis C virus and type 2 diabetes.

Authors:  Francesco Negro; Mahnaz Alaei
Journal:  World J Gastroenterol       Date:  2009-04-07       Impact factor: 5.742

9.  Sustained Virological Response Is Associated with a Decreased Risk of Posttransplant Diabetes Mellitus in Liver Transplant Recipients with Hepatitis C-Related Liver Disease.

Authors:  Giorgio A Roccaro; Robert Mitrani; Wei-Ting Hwang; Kimberly A Forde; K Rajender Reddy
Journal:  Liver Transpl       Date:  2018-12       Impact factor: 5.799

10.  Metabolic syndrome after liver transplantation: preventable illness or common consequence?

Authors:  Eric R Kallwitz
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.